FGP
AVNS

Freestone Grove Partners’s Avanos Medical AVNS Stock Holding History

Freestone Grove Partners’s Portfolio AVNS Stock Details AVNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25 Buy
+1
New +$23 ﹤0.01% 957

Other funds holding AVNS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NAM
Nexpoint Asset Management Dallas, Texas $1.5B AUM 83.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.72B AUM 70.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Freestone Grove Partners's AVNS Position: Q2 2026 in Review

Freestone Grove Partners opened a new position in Avanos Medical (AVNS) in Q2 2026: 1 share worth $25. The stake represents ﹤0.01% of the portfolio and ranks #957 among its holdings.

287 funds tracked by Wall St. Rank hold AVNS as of Q2 2026.

  • Freestone Grove Partners held 1 share of Avanos Medical worth $25 as of Q2 2026.
  • Avanos Medical was a new Freestone Grove Partners position in Q2 2026.
  • Avanos Medical made up ﹤0.01% of Freestone Grove Partners's portfolio in Q2 2026, its #957 holding.
  • 287 funds tracked by Wall St. Rank held Avanos Medical as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.